argenx reports Q3 2026 VYVGART sales of $1.7 billion, outlines pipeline timelinesOct 22Quarterly updateargenxefgartigimod alfa and hyaluronidase (human recombinant)
argenx registers Phase 2 trial of empasiprubart for Guillain-Barré syndromeSep 16Trial updateargenxempasiprubart
argenx registers Phase 2a empasiprubart trial in gMG; adimanebart PK study recruitingJun 29Weekly roundup, 2 itemsadimanebartargenx